Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Hodgkin Disease 2Burkitt Lymphoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Teratoma 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Heart Failure 1Glioma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Dendritic Cell Sarcoma, Interdigitating 1Choriocarcinoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 55fludarabine 29Methotrexate 25blinatumomab 22Dexamethasone 22Cytarabine 21Vincristine 20venetoclax 18fludarabine phosphate 15Specimen Handling 15Whole-Body Irradiation 13Stem Cell Transplantation 11Biopsy 11Tacrolimus 10Prednisone 10Mycophenolic Acid 10Mercaptopurine 10Daunorubicin 10Thiotepa 9Rituximab 9Melphalan 9Immunotherapy, Adoptive 9Doxorubicin 8pegaspargase 7Magnetic Resonance Spectroscopy 7Inotuzumab Ozogamicin 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7Calcium Dobesilate 7ponatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × pegfilgrastim × Clear all
NCT07224100 2026-04-16

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

University of Washington

Phase 2 Recruiting
33 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡